{"gene":"IRF4","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1995,"finding":"LSIRF/IRF4 is a lymphoid-specific member of the IRF family that binds the interferon-stimulated response element (ISRE) of the MHC class I promoter in vitro. Its expression is not induced by interferons but is induced by antigen-receptor-mediated stimuli (plant lectins, CD3, or IgM crosslinking).","method":"PCR cloning, in vitro DNA binding studies (ISRE binding), lymphoid-cell expression analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro DNA binding assay plus expression characterization, single lab, two orthogonal methods","pmids":["7541907"],"is_preprint":false},{"year":1996,"finding":"IRF4 (ICSAT/Pip/LSIRF) functions as a transcriptional repressor of interferon-regulated genes. Cotransfection experiments showed IRF4 represses gene activation induced by IFN stimulation or IRF-1 cotransfection, with a distinct repressive activity profile compared to IRF-2 and ICSBP. Differential binding affinities for distinct ICS motifs were established in vitro.","method":"Cotransfection reporter assays in N-Tera2 cells, in vitro DNA binding affinity comparisons","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assays plus in vitro binding, single lab, two orthogonal methods","pmids":["8657101"],"is_preprint":false},{"year":1998,"finding":"The DNA-binding domains of PU.1 and IRF4 form a cooperative ternary complex at immunoglobulin enhancer elements (lambdaB and kappaE3' sites). The minimal IRF4 DNA-binding domain maps to residues 20–137; residues 1–19 decrease IRF4 binding affinity 2- to 5-fold but all constructs bind better in the presence of PU.1's DNA-binding domain. Cooperative interaction requires proper spacing of PU.1 and IRF4 binding sites but is not dependent on phosphorylation of PU.1's PEST domain. NMR indicates the PEST domain of PU.1 and residues 1–19 of IRF4 may be intrinsically unstructured.","method":"Fluorescence polarization DNA-binding assays, NMR spectroscopy of 15N-labelled constructs, mutagenesis/truncation mapping","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution of cooperative DNA binding with domain mapping, fluorescence polarization, and NMR in a single rigorous study","pmids":["9642085"],"is_preprint":false},{"year":2002,"finding":"IRF4 can function as both a transcriptional repressor and activator depending on the DNA-binding motif engaged and its protein–protein interaction partners, most notably the Ets family member PU.1. Post-translational modification and nuclear translocation of IRF4 contribute to its transcriptional regulatory role.","method":"Review integrating prior experimental data (cotransfection assays, DNA-binding studies, nuclear translocation analyses)","journal":"Journal of interferon & cytokine research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review article; individual experiments cited but not independently re-validated in this paper","pmids":["11846983"],"is_preprint":false},{"year":2006,"finding":"IRF4 is required for post-germinal center plasma cell differentiation and for class-switch recombination in B cells. Conditional deletion of Irf4 in germinal center B cells abolished post-GC plasma cells, blocked memory B cell differentiation into plasma cells, impaired AID expression, and eliminated class-switch recombination. IRF4 acts upstream of Blimp-1 and XBP-1 in the plasma cell differentiation cascade.","method":"Conditional knockout (Cre-lox) in mice, immunological readouts (plasma cell numbers, CSR assays, AID expression), genetic epistasis with Blimp-1 and XBP-1","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with multiple orthogonal phenotypic readouts and epistasis positioning, broadly replicated finding","pmids":["16767092"],"is_preprint":false},{"year":2008,"finding":"IRF4 directly targets and activates MYC in activated B cells and myeloma, and MYC in turn directly transactivates IRF4, creating an autoregulatory circuit essential for myeloma cell survival. Genome-wide chromatin immunoprecipitation identified an extensive IRF4 target gene network, and RNAi-based genetic screen showed IRF4 knockdown is toxic to myeloma cell lines regardless of transforming oncogenic mechanism.","method":"RNAi loss-of-function genetic screen, gene expression profiling, genome-wide ChIP analysis, identification of MYC as direct IRF4 target","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP plus functional RNAi screen with multiple orthogonal methods in a single rigorous study, broadly cited and replicated concept","pmids":["18568025"],"is_preprint":false},{"year":2011,"finding":"IRF4 binds to and activates transcription through the IRF-Ets composite sequence (IECS) in myeloid progenitor cells. Ectopic IRF4 expression inhibits myeloid cell growth, promotes macrophage differentiation, and hinders granulocytic differentiation. Irf8−/−Irf4−/− double-knockout mice develop a more severe CML-like disease than Irf8−/− mice alone, demonstrating functional redundancy between IRF4 and IRF8 in suppressing granulocytic expansion.","method":"Ectopic expression in myeloid progenitors in vitro, double-knockout mouse model, reporter assays for IECS binding","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assays plus double-KO mouse epistasis, single lab","pmids":["22003407"],"is_preprint":false},{"year":2011,"finding":"IRF4 functions as a tumor suppressor in c-Myc-induced B cell leukemia. IRF4 heterozygous EμMyc mice developed pre-B cell leukemia with greatly accelerated kinetics. IRF4 reconstitution in leukemic cells induced p27kip1 and inhibited their expansion; IRF4-deficient leukemic cells showed loss of p27kip1 expression and inactivation of the wild-type IRF4 allele with Arf-p53 pathway defects.","method":"EμMyc transgenic mouse model crossed to IRF4+/− mice, IRF4 reconstitution experiments, p27kip1 expression analysis, Arf-p53 pathway assessment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse model plus reconstitution rescue experiment, single lab","pmids":["21818355"],"is_preprint":false},{"year":2013,"finding":"Smad2/3 and IRF4 cooperatively transactivate the Il9 promoter in Th9 cells. Smad2/3 physically interacts with IRF4 (co-immunoprecipitation), is recruited to the Il9 promoter by TGF-β, and requires IRF4 to activate Il9 transcription; conversely, IRF4 requires Smad2/3 for Il9 promoter binding and Th9 induction.","method":"T cell-specific Smad2/3 knockout mice, Co-IP of Smad2/3 with IRF4, ChIP at Il9 promoter, IRF4-deficient T cell experiments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional genetics, Co-IP of interaction, ChIP, and multiple knockout models in one study","pmids":["23913959"],"is_preprint":false},{"year":2013,"finding":"Low IRF4 expression is causally linked to CLL development: IRF4−/−Vh11 mice develop spontaneous early-onset CLL with 100% penetrance. IRF4 reconstitution in CLL cells inhibits their survival, establishing IRF4 as a causal tumor suppressor in this context.","method":"IRF4-deficient Vh11 knock-in mouse model, reconstitution of IRF4 in CLL cells, survival/apoptosis assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function mouse model plus reconstitution rescue, single lab","pmids":["23926303"],"is_preprint":false},{"year":2014,"finding":"IRF4 is a dominant transcriptional driver of thermogenesis in adipocytes, acting as a partner of PGC-1α. IRF4 is induced by cold and cAMP in adipocytes, directly interacts with PGC-1α (Co-IP), induces PGC-1α and PRDM16 expression, and drives Ucp1 expression. Knockout of IRF4 in UCP1+ cells reduces thermogenic gene expression, energy expenditure, and cold tolerance; overexpression promotes all three. PGC-1α-driven thermogenic gene expression requires IRF4.","method":"Adipocyte-specific IRF4 knockout mice, IRF4 overexpression in vivo, Co-immunoprecipitation of IRF4 with PGC-1α, cold/cAMP stimulation assays, Ucp1 reporter assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout plus overexpression in vivo, protein-protein interaction by Co-IP, and multiple orthogonal functional readouts in one study","pmids":["24995979"],"is_preprint":false},{"year":2014,"finding":"IRF4 is required in a B cell-intrinsic manner for germinal center B cell formation, independent of its role in plasma cell differentiation. Conditional deletion of Irf4 in mature B cells severely impaired GC formation as early as day 5 post-immunization. IRF4-deficient B cells in chimeric mice failed to participate in GCs after L. major or influenza infection.","method":"Conditional B cell-specific Irf4 knockout mice, mixed bone marrow chimeras, in vivo immunization models (protein antigen, L. major, influenza)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus chimeric rescue experiments with multiple immunization models, clear B cell-intrinsic phenotype","pmids":["24591370"],"is_preprint":false},{"year":2014,"finding":"IRF4 and BATF are both necessary for sustained CD8+ T cell effector function after LCMV infection. Irf4−/− CD8+ T cells showed initial proliferation but limited effector responses, causing viral persistence and protection from fatal immunopathology in Irf4−/− mice. Absence of BATF produced a similar phenotype.","method":"Irf4−/− mouse LCMV infection model, CD8+ T cell functional assays (cytotoxicity, viral clearance), comparison to BATF-deficient mice","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockout model with defined viral infection phenotype, single lab","pmids":["24531538"],"is_preprint":false},{"year":2014,"finding":"IRF4 concentration-dependently controls T helper cell fate: higher IRF4 levels promote Teff (Blimp-1+) fates at the expense of Tfh (Bcl6+) fates. Increased IRF4 abundance leads to its recruitment to lower-affinity binding sites in Teff cis-regulatory elements, including the Prdm1 locus. Orthogonal induction of Irf4 expression redirected Tfh cell fate toward Teff.","method":"Conditional IRF4 expression systems, ChIP-seq for IRF4 occupancy at distinct binding sites, T cell fate tracing, TCR signal strength manipulation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq, conditional expression, and fate-mapping with multiple orthogonal methods in one study","pmids":["28930660"],"is_preprint":false},{"year":2016,"finding":"mTORC2 and IL-4Rα-Stat6 pathways operate in parallel to induce IRF4 expression, which in turn drives increased glycolysis necessary for M2 (alternative) macrophage activation. Loss of mTORC2 in macrophages suppressed IRF4 induction and impaired M2 activation including glucose utilization.","method":"Myeloid-specific mTORC2 knockout mice, IL-4 stimulation assays, IRF4 expression measurements, metabolic flux assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO mouse model, pathway epistasis (mTORC2→Stat6→IRF4), and metabolic readouts with multiple methods","pmids":["27760338"],"is_preprint":false},{"year":2016,"finding":"KDM3A maintains expression of KLF2 and IRF4 in multiple myeloma through H3K9 demethylation. KLF2 directly activates IRF4 transcription, and IRF4 reciprocally upregulates KLF2, forming a positive autoregulatory circuit. Knockdown of KDM3A, KLF2, or IRF4 each decreases MM cell adhesion to bone marrow stromal cells and reduces MM cell homing, associated with decreased ITGB7 expression.","method":"siRNA knockdown, ChIP for H3K9me2 at KLF2/IRF4 loci, luciferase reporter assays for KLF2→IRF4 transcriptional activation, cell adhesion and homing assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for histone marks, reporter assays, knockdown phenotypes, and functional cell biology in one study with multiple orthogonal methods","pmids":["26728187"],"is_preprint":false},{"year":2016,"finding":"IRF4 and IRF8 cooperate with PU.1 to regulate early B cell development and suppress pre-B cell acute lymphoblastic leukemia. Combined PU.1/IRF4 deletion caused a partial pre-B cell developmental block and 100% leukemia incidence. PU.1/IRF4/IRF8 directly regulate Ikaros and Spi-B, established B-lineage tumor suppressor genes, and restoration of either rescued leukemic cell growth inhibition.","method":"PU.1/IRF4/IRF8 compound knockout mouse models, ChIP to show direct regulation of Ikaros and Spi-B, reconstitution of Ikaros/Spi-B in leukemic cells","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — compound KO mouse models with direct ChIP evidence of target gene regulation and rescue reconstitution experiments","pmids":["26932576"],"is_preprint":false},{"year":2017,"finding":"T cell exhaustion during chronic LCMV infection is driven by high TCR-induced IRF4, BATF, and NFATc1. These regulators promote inhibitory receptor expression (including PD-1) and impaired cellular metabolism, while repressing TCF1 required for memory T cell differentiation. Reducing IRF4 expression restored functional and metabolic properties and promoted memory-like T cell development.","method":"Transcriptional profiling of antigen-specific T cells from acute vs. chronic LCMV infection, IRF4 knockdown/reduction experiments, metabolic assays, inhibitory receptor expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — transcriptional profiling plus loss-of-function with multiple phenotypic readouts (metabolism, inhibitory receptors, TCF1 expression)","pmids":["29246443"],"is_preprint":false},{"year":2017,"finding":"IRF4 represses PD-1 expression and other molecules associated with T cell dysfunction in CD4+ T cells. IRF4 deletion increases chromatin accessibility at PD-1 cis-regulatory elements and enhances Helios binding there, leading to enhanced PD-1 expression and progressive CD4+ T cell dysfunction. The dysfunctional state was initially reversible by PD-1 ligand blockade.","method":"Irf4 conditional deletion in T cells, ATAC-seq for chromatin accessibility, ChIP for Helios at PD-1 cis-regulatory elements, allograft transplant model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus chromatin accessibility and ChIP at specific loci, mechanistic connection to Helios-PD1 axis established","pmids":["29221730"],"is_preprint":false},{"year":2017,"finding":"ITK kinase activity is required for Tr1 cell differentiation via the Ras/IRF4 pathway. Downstream of ITK, Ras activity induces IRF4 expression; constitutively active HRas rescues IRF4 expression and Tr1 cell differentiation in Itk−/− cells. IRF4 expression in Itk-deficient cells restores Tr1 cell development and suppressive function.","method":"Itk-deficient mouse model, constitutively active HRas rescue experiments, IRF4 reconstitution in Itk−/− cells, in vitro Tr1 cell differentiation assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiments placing IRF4 downstream of ITK-Ras, single lab","pmids":["28635957"],"is_preprint":false},{"year":2018,"finding":"The K59R IRF4 mutant found in adult T-cell leukemia is expressed at higher levels in the nucleus than WT IRF4 and is transcriptionally more active. IRF4 is bound to genomic regulatory DNA of its transcriptional targets in HTLV-1-transformed cell lines. Overexpression of both WT and K59R IRF4 from a constitutive promoter in murine bone marrow cells increased T lymphocyte abundance in vivo.","method":"Whole-exome sequencing, ChIP of IRF4 at target loci in HTLV-1-transformed cells, nuclear/cytoplasmic fractionation comparing WT vs K59R, retroviral transduction of murine bone marrow","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, nuclear localization fractionation, and in vivo reconstitution; single lab","pmids":["29540473"],"is_preprint":false},{"year":2019,"finding":"IRF4 activity in established plasma cells is required to regulate gene transcription specifying plasma cell identity and maintaining mitochondrial homeostasis. IRF4 loss in mature plasma cells triggers apoptosis, but this is not through direct regulation of the intrinsic apoptotic pathway; rather, inducible IRF4 deletion in the presence of BCL2 overexpression revealed the transcriptional (identity/mitochondrial) functions of IRF4 separately from its pro-survival role.","method":"Inducible Irf4 deletion system combined with BCL2 overexpression, gene expression profiling, mitochondrial function assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible KO with BCL2 rescue dissects two functions, single lab with clean genetic system","pmids":["31775034"],"is_preprint":false},{"year":2020,"finding":"IRF4 and NF-κB co-occupy super-enhancers in ATL cells and form a coherent feed-forward loop to coordinately regulate T-cell functional/developmental genes, as well as cancer-associated genes including MYC, CCR4, and BIRC3. Genetic inhibition of BIRC3 (a downstream effector) induced growth inhibition in ATL cells.","method":"Gene expression profiling of primary ATL samples, ChIP-seq for IRF4 and NF-κB binding at super-enhancers, BIRC3 genetic knockdown, growth inhibition assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus functional knockdown, single lab","pmids":["31972002"],"is_preprint":false},{"year":2020,"finding":"IRF4, either alone or in combination with BATF, directly controls a molecular program responsible for immunosuppression of CD4+ effector Tregs in tumors. Integration of transcriptomic and epigenomic data demonstrated direct IRF4 (and IRF4/BATF composite) binding at suppressive molecule gene loci; Irf4 deletion exclusively in Tregs delayed tumor growth in mice.","method":"Single-cell profiling, integration of transcriptomics and epigenomics (ATAC-seq/ChIP), Irf4 Treg-specific conditional knockout mouse tumor model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — Treg-specific KO mouse with direct epigenomic evidence of IRF4 binding at effector loci and multiple orthogonal methods","pmids":["32125291"],"is_preprint":false},{"year":2021,"finding":"Crystal structure of the IRF4/ISRE homodimeric complex revealed that homodimer formation is achieved exclusively through protein-DNA contacts with substantial DNA deformation, with no direct protein-protein contact. This contrasts with the IRF4/PU.1 heterodimeric complex where DNA-bound IRF4 physically contacts PU.1 to engage EICE1. Hotspot residues Arg98, Cys99, and Asn102 contact both consensus and non-consensus sequences via a flexible L1 loop. The CLL-associated IRF4L116R mutant binds DNA more robustly, providing a structural rationale for its gain-of-function.","method":"X-ray crystallography (crystal structure of IRF4/ISRE homodimer), mutagenesis of hotspot residues, comparison with heterodimeric complex","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis and mechanistic comparison between homo and heterodimeric forms in a single rigorous study","pmids":["33533913"],"is_preprint":false},{"year":2021,"finding":"BATF and IRF4 cooperate to counter T cell exhaustion in tumor-infiltrating CAR T cells. BATF overexpression in CAR T cells promoted survival, effector cytokine production, decreased inhibitory receptor/TOX expression, and supported memory T cell generation. These responses required BATF-IRF4 interaction, as a BATF variant unable to interact with IRF4 failed to improve antitumor responses.","method":"CAR T cell mouse tumor models, BATF overexpression, BATF mutant unable to interact with IRF4 (domain interaction requirement), flow cytometry, tumor growth assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain interaction mutant as mechanistic control, in vivo tumor models, multiple phenotypic readouts","pmids":["34282330"],"is_preprint":false},{"year":2021,"finding":"IRF4 negatively regulates BCR signaling in CLL cells by reducing AKT and ERK phosphorylation and calcium release; it suppresses expression of SYK (a key BCR signaling kinase) and IKAROS. IKAROS in turn promotes BCR signaling by reducing SHIP1 expression. IMiDs (lenalidomide/avadomide) induce IRF4 expression while down-regulating IKAROS, interfering with BCR-triggered survival advantage.","method":"IRF4 overexpression and siRNA knockdown in CLL cells, phospho-flow cytometry for AKT/ERK, calcium flux assays, SYK and IKAROS expression measurements, SHIP1 expression analysis","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with multiple downstream signaling readouts, single lab","pmids":["33623139"],"is_preprint":false},{"year":2021,"finding":"PC4, IKAROS, and IRF4 form a complex in mature B cells (Co-IP). IRF4 reciprocally induces PC4 expression via a super-enhancer. PC4 is required for IRF4 protein to increase upon B cell activation; PC4-deficient B cells show impaired plasma cell generation.","method":"B cell-specific PC4 knockout mice, Co-IP of PC4/IKAROS/IRF4 complex, super-enhancer analysis by ChIP, plasma cell differentiation assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of complex, KO mouse model, and super-enhancer ChIP, single lab","pmids":["33357426"],"is_preprint":false},{"year":2023,"finding":"A heterozygous IRF4 mutation (p.T95R) in the DNA-binding domain causes autosomal dominant combined immunodeficiency by acting as a multimorphic allele: it binds DNA with higher affinity than WT (gain-of-function hypermorph), has reduced transcriptional activity on canonical IRF4 target genes (hypomorphic), and binds noncanonical DNA sites to alter gene expression (neomorphic). IRF4T95R alters B cell maturation, immunoglobulin isotype switching, plasma cell differentiation, and TH17/TFH T cell populations.","method":"Patient genetics, knock-in mouse model of T95R, DNA binding affinity assays, transcriptomic profiling of patient cells, motif analysis of canonical vs. noncanonical binding sites","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — knock-in mouse model, direct DNA-binding affinity measurement, transcriptomic characterization, and mechanistic classification of multimorphic allele","pmids":["36662884"],"is_preprint":false},{"year":2023,"finding":"A heterozygous IRF4 missense variant in the interferon activation domain causes dominant primary immunodeficiency by altering IRF4 protein-protein interactions (identified by rapid immunoprecipitation mass spectrometry of endogenous proteins). Mutant IRF4 fails to efficiently regulate ISRE transcriptional activity and reduces BLIMP-1 and XBP1 expression, blocking plasma cell differentiation.","method":"Patient genetics, immunoprecipitation mass spectrometry of endogenous IRF4 protein partners, ISRE reporter assays, BLIMP-1/XBP1 expression in patient B cell lines","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous Co-IP mass spectrometry plus functional reporter assays and patient B cell lines, single study","pmids":["36917008"],"is_preprint":false},{"year":2023,"finding":"IRF4 in skeletal muscle transcriptionally regulates FSTL1 expression (established by dual luciferase reporter assay). Muscle-secreted FSTL1 acts on liver cells via distinct receptors (DIP2A/CD14) to regulate hepatic steatosis, inflammation, and fibrosis, defining an IRF4-FSTL1-DIP2A/CD14 inter-organ endocrine axis in NASH.","method":"Skeletal muscle-specific IRF4 knockout mice, proteomics, dual luciferase reporter assay for IRF4→FSTL1 transcription, co-culture experiments, AAV-mediated FSTL1 rescue in F4MKO mice","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO, luciferase reporter for direct transcriptional regulation, in vivo rescue by AAV-FSTL1, and co-culture mechanistic validation in one study","pmids":["37770480"],"is_preprint":false},{"year":2023,"finding":"IRF4 functions as a signal integrator in NK cells during cytomegalovirus infection, coordinating nutrient uptake (glucose and amino acid transport) necessary for NK cell expansion, differentiation, and memory generation. IRF4-deficient virus-specific NK cells were impaired in nutrient uptake and failed to expand or form memory.","method":"Irf4 conditional knockout in NK cells, MCMV infection model, nutrient uptake assays (glucose/amino acid transport), clonal expansion and memory NK cell assays","journal":"Nature immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO in NK cells with direct metabolic/nutrient uptake readouts, single lab","pmids":["37697097"],"is_preprint":false},{"year":2023,"finding":"The somatic mutation IRF4-C99R in Hodgkin lymphoma causes a fundamental alteration of IRF4 DNA binding: loss of binding to canonical IRF motifs and neomorphic gain of binding to canonical and non-canonical IRF composite elements (AICEs). IRF4-C99R blocks IRF4-dependent plasma cell induction and upregulates disease-specific genes in a non-canonical AICE-dependent manner.","method":"ChIP-seq of IRF4-C99R vs. WT in lymphoma cells, gene expression profiling, plasma cell differentiation assays, AICE motif analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq demonstrating altered DNA binding specificity, functional differentiation assays, motif-level mechanistic explanation","pmids":["37935654"],"is_preprint":false},{"year":2024,"finding":"ARID1A, a SWI/SNF complex member, is required for IRF4 expression in multiple myeloma and physically associates with IRF4 on chromatin. Deleting Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and blocks plasma cell differentiation. SWI/SNF inhibition causes rapid loss of IRF4-target gene expression and quenches MYC-driven oncogenic gene amplification.","method":"Multi-omics (functional genomics screening, spatial proteomics, chromatin mapping), co-occupancy of ARID1A and IRF4 by ChIP, Arid1a conditional KO in B cells, SMARCA2/4 inhibitor experiments","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO, chromatin co-occupancy, multi-omics, and pharmacological validation with multiple orthogonal methods","pmids":["38906156"],"is_preprint":false},{"year":2018,"finding":"PU.1 and IRF4 form a heterodimer that synergistically transactivates the Aldh1a2 (RALDH2) gene via an EICE motif at −1961/−1952 in dendritic cells. ChIP assays confirmed that both PU.1 and IRF4 bind the Aldh1a2 gene ~2 kb upstream of the TSS in bone marrow-derived and ex vivo DCs. Knockdown of either factor reduced RALDH2 mRNA and enzymatic activity.","method":"ChIP assay, EMSA, luciferase reporter assay, siRNA knockdown in BMDCs, ex vivo DC analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, EMSA, reporter and knockdown experiments in both in vitro and ex vivo systems, single lab","pmids":["30413670"],"is_preprint":false},{"year":2021,"finding":"IRAK4 phosphorylates both IRF4 and IRF5 in microglia, and forms a Myddosome complex with MyD88/IRF5/IRF4. Phosphorylated IRF4 translocates to the nucleus to drive anti-inflammatory microglial responses. IRAK4 inhibition blocks IRF4/IRF5 phosphorylation, reduces pro-inflammatory response, and increases neuronal viability after ischemia.","method":"Co-immunoprecipitation/Western blot of Myddosome complex, IRAK4 inhibitor treatment, nuclear translocation assays, OGD model in microglial cells","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of complex, pharmacological inhibition with multiple readouts, single lab","pmids":["33573200"],"is_preprint":false},{"year":2020,"finding":"IRF4 in skeletal muscle regulates glycogen metabolism by transcriptionally controlling PTG (protein targeting to glycogen). IRF4 knockout in skeletal muscle increases glycogen content and exercise capacity; IRF4 overexpression decreases both. PTG knockdown reverses the effects of IRF4 absence in vivo.","method":"Skeletal muscle-specific IRF4 knockout and overexpression mice, PTG knockdown in vivo, glycogen content measurements, exercise capacity assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO and OE plus in vivo rescue knockdown of downstream target PTG, single lab","pmids":["33042761"],"is_preprint":false}],"current_model":"IRF4 is a lymphoid- and immune-cell-restricted transcription factor that binds DNA as a homodimer (exclusively through protein-DNA contacts with DNA deformation) or as a heterodimer with partners such as PU.1 (via protein-protein contact on DNA at EICE/AICE elements), with binding-site affinity and partner availability determining whether it activates or represses target genes; it acts as a concentration-dependent signal integrator downstream of antigen receptor and cytokine signals to control B cell germinal center entry, class-switch recombination, and plasma cell differentiation (upstream of Blimp-1 and XBP-1), CD4+ T helper fate choice (Tfh vs. Teff), CD8+ T cell effector function and exhaustion, NK cell memory, macrophage alternative activation (via mTORC2-Stat6-IRF4-glycolysis axis), adipocyte thermogenesis (through direct interaction with PGC-1α), and skeletal muscle glycogen/FSTL1-mediated inter-organ crosstalk, while in malignancy it forms autoregulatory circuits with MYC and NF-κB and is maintained by epigenetic regulators including KDM3A and ARID1A/SWI/SNF."},"narrative":{"mechanistic_narrative":"IRF4 is a lymphoid- and immune-cell-restricted transcription factor that integrates antigen-receptor and cytokine signals to direct cell-fate decisions across the immune system and several metabolic tissues [PMID:7541907, PMID:28930660]. Originally identified as a lymphoid-specific IRF-family member that binds ISRE elements yet is induced by antigen-receptor stimuli rather than interferons, it acts as both repressor and activator depending on the DNA motif engaged and its partner proteins [PMID:7541907, PMID:8657101]. Structurally, IRF4 binds canonical ISRE sites as a homodimer formed exclusively through protein-DNA contacts with substantial DNA deformation and no protein-protein interface, whereas it engages composite EICE/AICE elements as a heterodimer in which DNA-bound IRF4 physically contacts partners such as PU.1 and BATF [PMID:33533913, PMID:9642085, PMID:34282330]. This concentration-dependent occupancy of high- versus low-affinity sites underlies its role as a signal integrator: in B cells IRF4 is required cell-intrinsically for germinal center formation, class-switch recombination, and post-germinal-center plasma cell differentiation upstream of Blimp-1 and XBP-1, and maintains plasma cell identity and mitochondrial homeostasis [PMID:24591370, PMID:16767092, PMID:31775034]. In T cells, graded IRF4 abundance steers Teff versus Tfh fate by redirecting occupancy to lower-affinity sites at the Prdm1 locus, sustains CD8+ effector function with BATF, and at high TCR-driven levels promotes exhaustion while repressing PD-1 in CD4+ cells [PMID:28930660, PMID:24531538, PMID:29246443, PMID:29221730]. Beyond lymphocytes, IRF4 drives M2 macrophage activation via an mTORC2-Stat6-IRF4-glycolysis axis, coordinates nutrient uptake for NK cell memory, partners with PGC-1α to control adipocyte thermogenesis, and transcriptionally governs muscle glycogen (via PTG) and FSTL1-mediated inter-organ crosstalk [PMID:27760338, PMID:37697097, PMID:24995979, PMID:33042761, PMID:37770480]. In malignancy IRF4 forms autoregulatory circuits with MYC and NF-κB and is maintained by epigenetic regulators KDM3A and ARID1A/SWI/SNF, acting as an essential survival factor in myeloma yet a tumor suppressor in c-Myc-driven and chronic lymphocytic leukemias [PMID:18568025, PMID:31972002, PMID:26728187, PMID:38906156, PMID:21818355, PMID:23926303]. Heterozygous DNA-binding-domain mutations (p.T95R, multimorphic) and interferon-activation-domain variants cause autosomal dominant combined immunodeficiency by altering DNA-binding specificity and protein interactions [PMID:36662884, PMID:36917008].","teleology":[{"year":1995,"claim":"Establishing IRF4 as a lymphoid-restricted IRF-family factor induced by antigen-receptor rather than interferon signals separated it from the classical interferon-response IRFs and pointed to a role in adaptive immunity.","evidence":"PCR cloning and in vitro ISRE-binding assays in lymphoid cells","pmids":["7541907"],"confidence":"Medium","gaps":["In vitro binding only; physiological target genes not defined","No loss-of-function phenotype established"]},{"year":1996,"claim":"Demonstrating that IRF4 can repress interferon-induced gene activation, with motif-dependent binding affinities, framed it as a context-dependent regulator rather than a simple activator.","evidence":"Cotransfection reporter assays and in vitro DNA-binding affinity comparisons","pmids":["8657101"],"confidence":"Medium","gaps":["Activator versus repressor switch not yet mechanistically explained","No partner protein identified"]},{"year":1998,"claim":"Reconstitution of a cooperative PU.1-IRF4 ternary complex on immunoglobulin enhancers defined the partner-dependent heterodimeric binding mode and mapped the IRF4 DNA-binding domain.","evidence":"Fluorescence polarization binding, NMR, and truncation mapping of PU.1/IRF4 domains","pmids":["9642085"],"confidence":"High","gaps":["Full-length protein behavior not tested","Genomic target repertoire of the complex unknown"]},{"year":2006,"claim":"Conditional deletion in germinal center B cells placed IRF4 upstream of Blimp-1 and XBP-1, defining it as a master regulator of class-switch recombination and plasma cell differentiation.","evidence":"Cre-lox conditional knockout mice with CSR, AID, and epistasis readouts","pmids":["16767092"],"confidence":"High","gaps":["Direct IRF4 target genes in this cascade not fully enumerated","Mechanism of concentration-dependent fate control not yet addressed"]},{"year":2008,"claim":"Genome-wide ChIP plus an RNAi lethality screen revealed an IRF4-MYC autoregulatory circuit essential for myeloma survival, establishing IRF4 as an oncogenic dependency.","evidence":"Genome-wide ChIP, expression profiling, and RNAi loss-of-function screen in myeloma lines","pmids":["18568025"],"confidence":"High","gaps":["Upstream maintenance of IRF4 in myeloma not defined here","Does not reconcile oncogenic versus tumor-suppressor contexts"]},{"year":2011,"claim":"Mouse genetics in distinct leukemia models showed IRF4 acts as a tumor suppressor in c-Myc-driven B-cell leukemia and cooperates redundantly with IRF8 in myeloid lineages, revealing strong context-dependence of its oncogenic role.","evidence":"EμMyc/IRF4+/- mice with reconstitution, and Irf8/Irf4 double-knockout myeloid models","pmids":["21818355","22003407"],"confidence":"Medium","gaps":["Molecular basis distinguishing tumor-suppressor versus oncogene roles unresolved","p27/Arf-p53 link correlative for direct regulation"]},{"year":2013,"claim":"Reciprocal genetics identified Smad2/3 as a physical IRF4 partner cooperatively activating Il9, and IRF4-deficient mouse models linked low IRF4 causally to CLL, extending its partner repertoire and tumor-suppressor function.","evidence":"Co-IP, ChIP at Il9, knockout T cells, and IRF4-/-Vh11 CLL mouse model with reconstitution","pmids":["23913959","23926303"],"confidence":"High","gaps":["Smad2/3-IRF4 interface not structurally mapped","CLL tumor-suppressor mechanism downstream of IRF4 incomplete"]},{"year":2014,"claim":"A cluster of studies established IRF4 as a B-cell-intrinsic requirement for germinal center entry, a BATF-dependent driver of CD8 effector function, and—surprisingly—a thermogenic transcription factor partnering PGC-1α in adipocytes, broadening its biology beyond lymphocytes.","evidence":"Conditional/chimeric B-cell and CD8 knockout infection models, plus adipocyte-specific KO/overexpression with PGC-1α Co-IP","pmids":["24591370","24531538","24995979"],"confidence":"High","gaps":["Direct IRF4 targets in each lineage incompletely mapped","How one factor switches between immune and metabolic programs unknown"]},{"year":2016,"claim":"Mechanistic dissection showed IRF4 abundance is set by parallel mTORC2-Stat6 input to drive M2 macrophage glycolysis, and that PU.1/IRF4/IRF8 jointly suppress B-ALL via Ikaros/Spi-B, while KDM3A-KLF2 maintains IRF4 in myeloma—connecting upstream signaling, epigenetics, and lineage tumor suppression.","evidence":"Myeloid mTORC2 KO with metabolic flux, compound PU.1/IRF4/IRF8 KO mice with ChIP/rescue, and KDM3A H3K9me ChIP/reporter/adhesion assays","pmids":["27760338","26932576","26728187"],"confidence":"High","gaps":["Direct mechanism coupling IRF4 to glycolytic gene induction not fully resolved","How IRF4 partitions oncogenic versus suppressive output across lineages unexplained"]},{"year":2017,"claim":"Quantitative studies defined IRF4 as a concentration-dependent signal integrator: graded levels redirect occupancy from high- to low-affinity Teff cis-elements (Tfh/Teff choice), while sustained high TCR-driven IRF4 promotes exhaustion yet IRF4 also represses PD-1 via chromatin control, resolving its dual role in T-cell function.","evidence":"ChIP-seq/conditional expression for Tfh/Teff, chronic LCMV profiling with IRF4 reduction, ATAC-seq/Helios ChIP at PD-1 elements, and ITK-Ras-IRF4 rescue","pmids":["28930660","29246443","29221730","28635957"],"confidence":"High","gaps":["Threshold-setting kinetics of IRF4 protein in vivo not quantified","Apparently opposing PD-1 effects across contexts not fully reconciled"]},{"year":2018,"claim":"Cancer-mutation and DC studies showed IRF4 activity is tuned by nuclear abundance (K59R in ATL) and by EICE-dependent synergy with PU.1 at the Aldh1a2 locus, linking gain-of-function mutations and partner cooperativity to altered output.","evidence":"Exome sequencing, ChIP and nuclear fractionation of WT vs K59R, plus ChIP/EMSA/reporter/knockdown of PU.1-IRF4 at Aldh1a2 in DCs","pmids":["29540473","30413670"],"confidence":"Medium","gaps":["Mechanism elevating K59R nuclear levels undefined","Single-lab observations awaiting independent confirmation"]},{"year":2019,"claim":"Separating IRF4's survival from identity functions using inducible deletion plus BCL2 rescue showed IRF4 maintains plasma cell identity and mitochondrial homeostasis through transcription independent of direct apoptotic control.","evidence":"Inducible Irf4 deletion with BCL2 overexpression, expression profiling, mitochondrial assays","pmids":["31775034"],"confidence":"Medium","gaps":["Direct mitochondrial target genes not defined","Single genetic system"]},{"year":2020,"claim":"Genome-wide and tissue-specific work established IRF4-NF-κB feed-forward super-enhancer circuits in ATL, IRF4-directed Treg immunosuppression, and IRF4 control of muscle glycogen via PTG, unifying its roles in malignancy, tumor immunity, and metabolism.","evidence":"ChIP-seq of IRF4/NF-κB at super-enhancers with BIRC3 knockdown, Treg-specific Irf4 KO tumor model with epigenomics, and muscle IRF4 KO/OE with PTG rescue","pmids":["31972002","32125291","33042761"],"confidence":"High","gaps":["How super-enhancer co-occupancy is nucleated unclear","Direct versus indirect metabolic targets only partly resolved"]},{"year":2021,"claim":"A crystal structure resolved the contact-free homodimeric versus PU.1-contacting heterodimeric binding modes and rationalized CLL gain-of-function (L116R), while functional studies extended IRF4 partnerships to BATF (anti-exhaustion in CAR T), the PC4/IKAROS complex, and BCR-signaling suppression in CLL.","evidence":"X-ray crystallography with hotspot mutagenesis, CAR T tumor models with BATF interaction-deficient mutant, PC4/IKAROS/IRF4 Co-IP, and CLL gain/loss-of-function signaling assays","pmids":["33533913","34282330","33357426","33623139"],"confidence":"High","gaps":["Structural basis of heterodimers beyond PU.1 not solved","In vivo relevance of PC4/IKAROS complex incompletely defined"]},{"year":2023,"claim":"Human germline IRF4 mutations (multimorphic p.T95R, interferon-activation-domain variant) were shown to cause autosomal dominant immunodeficiency, and somatic C99R in Hodgkin lymphoma was shown to neomorphically rewire DNA-binding to AICEs, formally linking altered DNA-binding/partner specificity to disease; parallel work extended IRF4 to NK-cell memory metabolism and a muscle-FSTL1-liver endocrine axis.","evidence":"Knock-in mice and patient cells with binding/transcriptomic profiling, ChIP-seq of C99R, NK-specific KO with nutrient-uptake assays, and muscle-specific KO with FSTL1 reporter/AAV rescue","pmids":["36662884","36917008","37935654","37697097","37770480"],"confidence":"High","gaps":["Genotype-phenotype spectrum of multimorphic alleles incompletely mapped","Receptors/effectors downstream in metabolic axes only partly defined"]},{"year":2024,"claim":"Identifying ARID1A/SWI/SNF as a chromatin partner required for IRF4 expression and IRF4-target/MYC oncogenic programs in myeloma defined a therapeutically actionable epigenetic dependency maintaining IRF4 networks.","evidence":"Multi-omics with ARID1A-IRF4 chromatin co-occupancy, Arid1a B-cell KO, and SMARCA2/4 inhibitor experiments","pmids":["38906156"],"confidence":"High","gaps":["Direct physical interface between ARID1A and IRF4 not mapped","Generalizability beyond myeloma untested"]},{"year":null,"claim":"How a single transcription factor mechanistically partitions opposing outputs—oncogene versus tumor suppressor, effector versus exhaustion, immune versus metabolic programs—across cell types remains the central open question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking IRF4 dose, partner availability, and site affinity to lineage-specific output","Post-translational control of IRF4 abundance/localization across tissues incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,4,13,24,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,24,28,32]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,8,10,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20,35]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[13,32,33]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,11,13,14,31]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,24,32]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,22,28,32,33]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[10,14,30,36]}],"complexes":["IRF4/PU.1 heterodimer","IRF4/BATF complex","PC4/IKAROS/IRF4 complex","MyD88/IRF5/IRF4 Myddosome"],"partners":["SPI1","BATF","SMAD3","PPARGC1A","IKZF1","SUB1","ARID1A","IRF8"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15306","full_name":"Interferon regulatory factor 4","aliases":["Lymphocyte-specific interferon regulatory factor","LSIRF","Multiple myeloma oncogene 1","NF-EM5"],"length_aa":451,"mass_kda":51.8,"function":"Transcriptional activator. Binds to the interferon-stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q15306/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IRF4","classification":"Not Classified","n_dependent_lines":87,"n_total_lines":1208,"dependency_fraction":0.07201986754966887},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IRF4","total_profiled":1310},"omim":[{"mim_id":"621097","title":"IMMUNODEFICIENCY 131; IMD131","url":"https://www.omim.org/entry/621097"},{"mim_id":"614983","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 2; BATF2","url":"https://www.omim.org/entry/614983"},{"mim_id":"612558","title":"LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 4","url":"https://www.omim.org/entry/612558"},{"mim_id":"612476","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE; BATF","url":"https://www.omim.org/entry/612476"},{"mim_id":"612470","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 3; BATF3","url":"https://www.omim.org/entry/612470"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":38.6},{"tissue":"lymphoid tissue","ntpm":24.5}],"url":"https://www.proteinatlas.org/search/IRF4"},"hgnc":{"alias_symbol":["LSIRF"],"prev_symbol":["MUM1"]},"alphafold":{"accession":"Q15306","domains":[{"cath_id":"1.10.10.10","chopping":"22-132","consensus_level":"high","plddt":92.5914,"start":22,"end":132},{"cath_id":"2.60.200.10","chopping":"246-425","consensus_level":"high","plddt":89.8214,"start":246,"end":425}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15306","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15306-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15306-F1-predicted_aligned_error_v6.png","plddt_mean":71.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IRF4","jax_strain_url":"https://www.jax.org/strain/search?query=IRF4"},"sequence":{"accession":"Q15306","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15306.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15306/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15306"}},"corpus_meta":[{"pmid":"16767092","id":"PMC_16767092","title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16767092","citation_count":634,"is_preprint":false},{"pmid":"18568025","id":"PMC_18568025","title":"IRF4 addiction in multiple myeloma.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18568025","citation_count":591,"is_preprint":false},{"pmid":"27760338","id":"PMC_27760338","title":"Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27760338","citation_count":520,"is_preprint":false},{"pmid":"25599561","id":"PMC_25599561","title":"The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells.","date":"2015","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25599561","citation_count":469,"is_preprint":false},{"pmid":"29246443","id":"PMC_29246443","title":"Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29246443","citation_count":405,"is_preprint":false},{"pmid":"34282330","id":"PMC_34282330","title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells.","date":"2021","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34282330","citation_count":298,"is_preprint":false},{"pmid":"24995979","id":"PMC_24995979","title":"IRF4 is a key thermogenic transcriptional partner of PGC-1α.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/24995979","citation_count":267,"is_preprint":false},{"pmid":"7541907","id":"PMC_7541907","title":"Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE).","date":"1995","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/7541907","citation_count":214,"is_preprint":false},{"pmid":"24782159","id":"PMC_24782159","title":"IRF4 at the crossroads of effector T-cell fate decision.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24782159","citation_count":182,"is_preprint":false},{"pmid":"8657101","id":"PMC_8657101","title":"A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8657101","citation_count":182,"is_preprint":false},{"pmid":"19383829","id":"PMC_19383829","title":"IRF4: Immunity. Malignancy! Therapy?","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19383829","citation_count":168,"is_preprint":false},{"pmid":"32125291","id":"PMC_32125291","title":"IRF4 instructs effector Treg differentiation and immune suppression in human cancer.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32125291","citation_count":147,"is_preprint":false},{"pmid":"22500833","id":"PMC_22500833","title":"The diverse roles of IRF4 in late germinal center B-cell differentiation.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22500833","citation_count":120,"is_preprint":false},{"pmid":"28930660","id":"PMC_28930660","title":"The IRF4 Gene Regulatory Module Functions as a Read-Write Integrator to Dynamically Coordinate T Helper Cell Fate.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28930660","citation_count":109,"is_preprint":false},{"pmid":"27826752","id":"PMC_27826752","title":"Essential role of interferon regulatory factor 4 (IRF4) in immune cell development.","date":"2016","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/27826752","citation_count":103,"is_preprint":false},{"pmid":"31738823","id":"PMC_31738823","title":"Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31738823","citation_count":100,"is_preprint":false},{"pmid":"23913959","id":"PMC_23913959","title":"Smad2/3 and IRF4 play a cooperative role in IL-9-producing T cell induction.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23913959","citation_count":97,"is_preprint":false},{"pmid":"19812605","id":"PMC_19812605","title":"IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.","date":"2009","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19812605","citation_count":97,"is_preprint":false},{"pmid":"24591370","id":"PMC_24591370","title":"Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24591370","citation_count":96,"is_preprint":false},{"pmid":"25359993","id":"PMC_25359993","title":"Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25359993","citation_count":95,"is_preprint":false},{"pmid":"26728187","id":"PMC_26728187","title":"The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26728187","citation_count":92,"is_preprint":false},{"pmid":"29221730","id":"PMC_29221730","title":"Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29221730","citation_count":82,"is_preprint":false},{"pmid":"22003407","id":"PMC_22003407","title":"Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22003407","citation_count":82,"is_preprint":false},{"pmid":"23010632","id":"PMC_23010632","title":"Targeting IRF4 in autoimmune diseases.","date":"2012","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23010632","citation_count":69,"is_preprint":false},{"pmid":"24531538","id":"PMC_24531538","title":"IRF4 and BATF are critical for CD8⁺ T-cell function following infection with LCMV.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24531538","citation_count":69,"is_preprint":false},{"pmid":"28635957","id":"PMC_28635957","title":"ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28635957","citation_count":65,"is_preprint":false},{"pmid":"20182347","id":"PMC_20182347","title":"MUM1/IRF4: A Review.","date":"2010","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/20182347","citation_count":64,"is_preprint":false},{"pmid":"17138822","id":"PMC_17138822","title":"IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17138822","citation_count":64,"is_preprint":false},{"pmid":"31775034","id":"PMC_31775034","title":"IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31775034","citation_count":63,"is_preprint":false},{"pmid":"11846983","id":"PMC_11846983","title":"The role of IRF-4 in transcriptional regulation.","date":"2002","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/11846983","citation_count":61,"is_preprint":false},{"pmid":"11846982","id":"PMC_11846982","title":"The role of IRF-4 in B and T cell activation and differentiation.","date":"2002","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/11846982","citation_count":55,"is_preprint":false},{"pmid":"35443173","id":"PMC_35443173","title":"Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35443173","citation_count":53,"is_preprint":false},{"pmid":"30098518","id":"PMC_30098518","title":"IRF4 in multiple myeloma-Biology, disease and therapeutic target.","date":"2018","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/30098518","citation_count":52,"is_preprint":false},{"pmid":"26932576","id":"PMC_26932576","title":"PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26932576","citation_count":52,"is_preprint":false},{"pmid":"34728538","id":"PMC_34728538","title":"SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34728538","citation_count":49,"is_preprint":false},{"pmid":"34654055","id":"PMC_34654055","title":"Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34654055","citation_count":49,"is_preprint":false},{"pmid":"27601624","id":"PMC_27601624","title":"Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/27601624","citation_count":48,"is_preprint":false},{"pmid":"25506356","id":"PMC_25506356","title":"IRF4 and IRF8: Governing the virtues of B Lymphocytes.","date":"2014","source":"Frontiers in biology","url":"https://pubmed.ncbi.nlm.nih.gov/25506356","citation_count":44,"is_preprint":false},{"pmid":"23926303","id":"PMC_23926303","title":"A role for IRF4 in the development of CLL.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926303","citation_count":43,"is_preprint":false},{"pmid":"29954751","id":"PMC_29954751","title":"CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29954751","citation_count":42,"is_preprint":false},{"pmid":"21818355","id":"PMC_21818355","title":"IRF4 is a suppressor of c-Myc induced B cell leukemia.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21818355","citation_count":38,"is_preprint":false},{"pmid":"37770480","id":"PMC_37770480","title":"Metabolic crosstalk between skeletal muscle cells and liver through IRF4-FSTL1 in nonalcoholic steatohepatitis.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37770480","citation_count":37,"is_preprint":false},{"pmid":"36662884","id":"PMC_36662884","title":"A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36662884","citation_count":36,"is_preprint":false},{"pmid":"28566276","id":"PMC_28566276","title":"Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28566276","citation_count":36,"is_preprint":false},{"pmid":"28538176","id":"PMC_28538176","title":"Tonic LAT-HDAC7 Signals Sustain Nur77 and Irf4 Expression to Tune Naive CD4 T Cells.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28538176","citation_count":34,"is_preprint":false},{"pmid":"9642085","id":"PMC_9642085","title":"Cooperative interaction between the DNA-binding domains of PU.1 and IRF4.","date":"1998","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9642085","citation_count":34,"is_preprint":false},{"pmid":"31972002","id":"PMC_31972002","title":"Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31972002","citation_count":33,"is_preprint":false},{"pmid":"30171029","id":"PMC_30171029","title":"DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.","date":"2018","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/30171029","citation_count":33,"is_preprint":false},{"pmid":"31089186","id":"PMC_31089186","title":"IRF4-dependent dendritic cells regulate CD8+ T-cell differentiation and memory responses in influenza infection.","date":"2019","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31089186","citation_count":32,"is_preprint":false},{"pmid":"37555980","id":"PMC_37555980","title":"Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.","date":"2023","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37555980","citation_count":31,"is_preprint":false},{"pmid":"38906156","id":"PMC_38906156","title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38906156","citation_count":30,"is_preprint":false},{"pmid":"36077849","id":"PMC_36077849","title":"IRF4 as an Oncogenic Master Transcription Factor.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36077849","citation_count":30,"is_preprint":false},{"pmid":"37697097","id":"PMC_37697097","title":"Control of nutrient uptake by IRF4 orchestrates innate immune memory.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37697097","citation_count":29,"is_preprint":false},{"pmid":"21114485","id":"PMC_21114485","title":"IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.","date":"2010","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/21114485","citation_count":29,"is_preprint":false},{"pmid":"36495369","id":"PMC_36495369","title":"The dynamic functions of IRF4 in B cell malignancies.","date":"2022","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36495369","citation_count":28,"is_preprint":false},{"pmid":"30988114","id":"PMC_30988114","title":"GM-CSF- and IRF4-Dependent Signaling Can Regulate Myeloid Cell Numbers and the Macrophage Phenotype during Inflammation.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30988114","citation_count":27,"is_preprint":false},{"pmid":"36159833","id":"PMC_36159833","title":"Jmjd3/IRF4 axis aggravates myeloid fibroblast activation and m2 macrophage to myofibroblast transition in renal fibrosis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36159833","citation_count":27,"is_preprint":false},{"pmid":"36814912","id":"PMC_36814912","title":"Regulatory effects of IRF4 on immune cells in the tumor microenvironment.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36814912","citation_count":26,"is_preprint":false},{"pmid":"28755520","id":"PMC_28755520","title":"Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells.","date":"2017","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/28755520","citation_count":26,"is_preprint":false},{"pmid":"33533913","id":"PMC_33533913","title":"Structural determinants of the IRF4/DNA homodimeric complex.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33533913","citation_count":25,"is_preprint":false},{"pmid":"36081178","id":"PMC_36081178","title":"Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.","date":"2022","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36081178","citation_count":25,"is_preprint":false},{"pmid":"33357426","id":"PMC_33357426","title":"Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33357426","citation_count":25,"is_preprint":false},{"pmid":"39501302","id":"PMC_39501302","title":"METTL3 facilitates kidney injury through promoting IRF4-mediated plasma cell infiltration via an m6A-dependent manner in systemic lupus erythematosus.","date":"2024","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39501302","citation_count":24,"is_preprint":false},{"pmid":"11846984","id":"PMC_11846984","title":"IRF-4 activities in HTLV-I-induced T cell leukemogenesis.","date":"2002","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/11846984","citation_count":24,"is_preprint":false},{"pmid":"21919915","id":"PMC_21919915","title":"Increased expression of IRF4 and ETS1 in CD4+ cells from patients with intermittent allergic rhinitis.","date":"2011","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/21919915","citation_count":24,"is_preprint":false},{"pmid":"33042761","id":"PMC_33042761","title":"IRF4 in Skeletal Muscle Regulates Exercise Capacity via PTG/Glycogen Pathway.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33042761","citation_count":24,"is_preprint":false},{"pmid":"28808358","id":"PMC_28808358","title":"MBD2 Regulates Th17 Cell Differentiation and Experimental Severe Asthma by Affecting IRF4 Expression.","date":"2017","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/28808358","citation_count":24,"is_preprint":false},{"pmid":"33573200","id":"PMC_33573200","title":"Phosphorylation of Microglial IRF5 and IRF4 by IRAK4 Regulates Inflammatory Responses to Ischemia.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33573200","citation_count":24,"is_preprint":false},{"pmid":"32467029","id":"PMC_32467029","title":"A Synchronous IRF4-Dependent Gene Regulatory Network in B and Helper T Cells Orchestrating the Antibody Response.","date":"2020","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32467029","citation_count":23,"is_preprint":false},{"pmid":"29540473","id":"PMC_29540473","title":"An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29540473","citation_count":23,"is_preprint":false},{"pmid":"31537531","id":"PMC_31537531","title":"B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31537531","citation_count":22,"is_preprint":false},{"pmid":"33284947","id":"PMC_33284947","title":"Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33284947","citation_count":21,"is_preprint":false},{"pmid":"36470475","id":"PMC_36470475","title":"Large B-cell lymphoma with IRF4 gene rearrangements: Differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients.","date":"2022","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36470475","citation_count":21,"is_preprint":false},{"pmid":"33503299","id":"PMC_33503299","title":"B cell lymphoma with IRF4 rearrangement: A clinicopathological study of 13 cases.","date":"2021","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/33503299","citation_count":20,"is_preprint":false},{"pmid":"35472072","id":"PMC_35472072","title":"Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35472072","citation_count":19,"is_preprint":false},{"pmid":"35091544","id":"PMC_35091544","title":"KLF2 up-regulates IRF4/HDAC7 to protect neonatal rats from hypoxic-ischemic brain damage.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35091544","citation_count":19,"is_preprint":false},{"pmid":"31949143","id":"PMC_31949143","title":"Genomic programming of IRF4-expressing human Langerhans cells.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31949143","citation_count":18,"is_preprint":false},{"pmid":"19821826","id":"PMC_19821826","title":"IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.","date":"2009","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19821826","citation_count":18,"is_preprint":false},{"pmid":"33623139","id":"PMC_33623139","title":"IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.","date":"2021","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/33623139","citation_count":18,"is_preprint":false},{"pmid":"37935654","id":"PMC_37935654","title":"Transcriptional reprogramming by mutated IRF4 in lymphoma.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37935654","citation_count":16,"is_preprint":false},{"pmid":"35059038","id":"PMC_35059038","title":"Molecular interactions of IRF4 in B cell development and malignancies.","date":"2021","source":"Biophysical reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35059038","citation_count":15,"is_preprint":false},{"pmid":"38164749","id":"PMC_38164749","title":"IRF4 induces M1 macrophage polarization and aggravates ulcerative colitis progression by the Bcl6-dependent STAT3 pathway.","date":"2024","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38164749","citation_count":15,"is_preprint":false},{"pmid":"30413670","id":"PMC_30413670","title":"The Transcription Factors PU.1 and IRF4 Determine Dendritic Cell-Specific Expression of RALDH2.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30413670","citation_count":15,"is_preprint":false},{"pmid":"33249782","id":"PMC_33249782","title":"Bach2 overexpression represses Th9 cell differentiation by suppressing IRF4 expression in systemic lupus erythematosus.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/33249782","citation_count":15,"is_preprint":false},{"pmid":"39356034","id":"PMC_39356034","title":"Targeting Immunoproteasome in Polarized Macrophages Ameliorates Experimental Emphysema Via Activating NRF1/2-P62 Axis and Suppressing IRF4 Transcription.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39356034","citation_count":14,"is_preprint":false},{"pmid":"26544714","id":"PMC_26544714","title":"IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26544714","citation_count":14,"is_preprint":false},{"pmid":"38615379","id":"PMC_38615379","title":"Roles of IRF4 in various immune cells in systemic lupus erythematosus.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38615379","citation_count":14,"is_preprint":false},{"pmid":"35993451","id":"PMC_35993451","title":"Postbiotics engage IRF4 in adipocytes to promote sex-dependent changes in blood glucose during obesity.","date":"2022","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/35993451","citation_count":14,"is_preprint":false},{"pmid":"30586599","id":"PMC_30586599","title":"Myeloid cell IRF4 signaling protects neonatal brains from hypoxic ischemic encephalopathy.","date":"2018","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/30586599","citation_count":14,"is_preprint":false},{"pmid":"37648017","id":"PMC_37648017","title":"Dihydroquercetin (DHQ) ameliorates LPS-induced acute lung injury by regulating macrophage M2 polarization through IRF4/miR-132-3p/FBXW7 axis.","date":"2023","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37648017","citation_count":14,"is_preprint":false},{"pmid":"36917008","id":"PMC_36917008","title":"A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency.","date":"2023","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36917008","citation_count":13,"is_preprint":false},{"pmid":"34929342","id":"PMC_34929342","title":"IRF4 transcriptionally activate HOTAIRM1, which in turn regulates IRF4 expression, thereby affecting Th9 cell differentiation and involved in allergic rhinitis.","date":"2021","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/34929342","citation_count":13,"is_preprint":false},{"pmid":"36194494","id":"PMC_36194494","title":"IRF4 expression by lung dendritic cells drives acute but not Trm cell-dependent memory Th2 responses.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36194494","citation_count":12,"is_preprint":false},{"pmid":"36810796","id":"PMC_36810796","title":"Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer's ring in adults.","date":"2023","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36810796","citation_count":12,"is_preprint":false},{"pmid":"38862817","id":"PMC_38862817","title":"ABBV-744 alleviates LPS-induced neuroinflammation via regulation of BATF2-IRF4-STAT1/3/5 axis.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38862817","citation_count":12,"is_preprint":false},{"pmid":"35908629","id":"PMC_35908629","title":"Lineage- and Stage-Specific Oncogenicity of IRF4.","date":"2022","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35908629","citation_count":11,"is_preprint":false},{"pmid":"35504924","id":"PMC_35504924","title":"IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35504924","citation_count":11,"is_preprint":false},{"pmid":"36047964","id":"PMC_36047964","title":"Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/36047964","citation_count":11,"is_preprint":false},{"pmid":"34253454","id":"PMC_34253454","title":"IRF4 ablation in B cells abrogates allogeneic B cell responses and prevents chronic transplant rejection.","date":"2021","source":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/34253454","citation_count":11,"is_preprint":false},{"pmid":"33325591","id":"PMC_33325591","title":"Acly promotes metabolic reprogramming and induction of IRF4 during early CD8+ T cell activation.","date":"2020","source":"Cytometry. Part A : the journal of the International Society for Analytical Cytology","url":"https://pubmed.ncbi.nlm.nih.gov/33325591","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47558,"output_tokens":9806,"usd":0.144882,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20375,"output_tokens":6139,"usd":0.127675,"stage2_stop_reason":"end_turn"},"total_usd":0.272557,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"LSIRF/IRF4 is a lymphoid-specific member of the IRF family that binds the interferon-stimulated response element (ISRE) of the MHC class I promoter in vitro. Its expression is not induced by interferons but is induced by antigen-receptor-mediated stimuli (plant lectins, CD3, or IgM crosslinking).\",\n      \"method\": \"PCR cloning, in vitro DNA binding studies (ISRE binding), lymphoid-cell expression analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro DNA binding assay plus expression characterization, single lab, two orthogonal methods\",\n      \"pmids\": [\"7541907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IRF4 (ICSAT/Pip/LSIRF) functions as a transcriptional repressor of interferon-regulated genes. Cotransfection experiments showed IRF4 represses gene activation induced by IFN stimulation or IRF-1 cotransfection, with a distinct repressive activity profile compared to IRF-2 and ICSBP. Differential binding affinities for distinct ICS motifs were established in vitro.\",\n      \"method\": \"Cotransfection reporter assays in N-Tera2 cells, in vitro DNA binding affinity comparisons\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assays plus in vitro binding, single lab, two orthogonal methods\",\n      \"pmids\": [\"8657101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The DNA-binding domains of PU.1 and IRF4 form a cooperative ternary complex at immunoglobulin enhancer elements (lambdaB and kappaE3' sites). The minimal IRF4 DNA-binding domain maps to residues 20–137; residues 1–19 decrease IRF4 binding affinity 2- to 5-fold but all constructs bind better in the presence of PU.1's DNA-binding domain. Cooperative interaction requires proper spacing of PU.1 and IRF4 binding sites but is not dependent on phosphorylation of PU.1's PEST domain. NMR indicates the PEST domain of PU.1 and residues 1–19 of IRF4 may be intrinsically unstructured.\",\n      \"method\": \"Fluorescence polarization DNA-binding assays, NMR spectroscopy of 15N-labelled constructs, mutagenesis/truncation mapping\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution of cooperative DNA binding with domain mapping, fluorescence polarization, and NMR in a single rigorous study\",\n      \"pmids\": [\"9642085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IRF4 can function as both a transcriptional repressor and activator depending on the DNA-binding motif engaged and its protein–protein interaction partners, most notably the Ets family member PU.1. Post-translational modification and nuclear translocation of IRF4 contribute to its transcriptional regulatory role.\",\n      \"method\": \"Review integrating prior experimental data (cotransfection assays, DNA-binding studies, nuclear translocation analyses)\",\n      \"journal\": \"Journal of interferon & cytokine research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review article; individual experiments cited but not independently re-validated in this paper\",\n      \"pmids\": [\"11846983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IRF4 is required for post-germinal center plasma cell differentiation and for class-switch recombination in B cells. Conditional deletion of Irf4 in germinal center B cells abolished post-GC plasma cells, blocked memory B cell differentiation into plasma cells, impaired AID expression, and eliminated class-switch recombination. IRF4 acts upstream of Blimp-1 and XBP-1 in the plasma cell differentiation cascade.\",\n      \"method\": \"Conditional knockout (Cre-lox) in mice, immunological readouts (plasma cell numbers, CSR assays, AID expression), genetic epistasis with Blimp-1 and XBP-1\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with multiple orthogonal phenotypic readouts and epistasis positioning, broadly replicated finding\",\n      \"pmids\": [\"16767092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF4 directly targets and activates MYC in activated B cells and myeloma, and MYC in turn directly transactivates IRF4, creating an autoregulatory circuit essential for myeloma cell survival. Genome-wide chromatin immunoprecipitation identified an extensive IRF4 target gene network, and RNAi-based genetic screen showed IRF4 knockdown is toxic to myeloma cell lines regardless of transforming oncogenic mechanism.\",\n      \"method\": \"RNAi loss-of-function genetic screen, gene expression profiling, genome-wide ChIP analysis, identification of MYC as direct IRF4 target\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP plus functional RNAi screen with multiple orthogonal methods in a single rigorous study, broadly cited and replicated concept\",\n      \"pmids\": [\"18568025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF4 binds to and activates transcription through the IRF-Ets composite sequence (IECS) in myeloid progenitor cells. Ectopic IRF4 expression inhibits myeloid cell growth, promotes macrophage differentiation, and hinders granulocytic differentiation. Irf8−/−Irf4−/− double-knockout mice develop a more severe CML-like disease than Irf8−/− mice alone, demonstrating functional redundancy between IRF4 and IRF8 in suppressing granulocytic expansion.\",\n      \"method\": \"Ectopic expression in myeloid progenitors in vitro, double-knockout mouse model, reporter assays for IECS binding\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assays plus double-KO mouse epistasis, single lab\",\n      \"pmids\": [\"22003407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF4 functions as a tumor suppressor in c-Myc-induced B cell leukemia. IRF4 heterozygous EμMyc mice developed pre-B cell leukemia with greatly accelerated kinetics. IRF4 reconstitution in leukemic cells induced p27kip1 and inhibited their expansion; IRF4-deficient leukemic cells showed loss of p27kip1 expression and inactivation of the wild-type IRF4 allele with Arf-p53 pathway defects.\",\n      \"method\": \"EμMyc transgenic mouse model crossed to IRF4+/− mice, IRF4 reconstitution experiments, p27kip1 expression analysis, Arf-p53 pathway assessment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse model plus reconstitution rescue experiment, single lab\",\n      \"pmids\": [\"21818355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Smad2/3 and IRF4 cooperatively transactivate the Il9 promoter in Th9 cells. Smad2/3 physically interacts with IRF4 (co-immunoprecipitation), is recruited to the Il9 promoter by TGF-β, and requires IRF4 to activate Il9 transcription; conversely, IRF4 requires Smad2/3 for Il9 promoter binding and Th9 induction.\",\n      \"method\": \"T cell-specific Smad2/3 knockout mice, Co-IP of Smad2/3 with IRF4, ChIP at Il9 promoter, IRF4-deficient T cell experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional genetics, Co-IP of interaction, ChIP, and multiple knockout models in one study\",\n      \"pmids\": [\"23913959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Low IRF4 expression is causally linked to CLL development: IRF4−/−Vh11 mice develop spontaneous early-onset CLL with 100% penetrance. IRF4 reconstitution in CLL cells inhibits their survival, establishing IRF4 as a causal tumor suppressor in this context.\",\n      \"method\": \"IRF4-deficient Vh11 knock-in mouse model, reconstitution of IRF4 in CLL cells, survival/apoptosis assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function mouse model plus reconstitution rescue, single lab\",\n      \"pmids\": [\"23926303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF4 is a dominant transcriptional driver of thermogenesis in adipocytes, acting as a partner of PGC-1α. IRF4 is induced by cold and cAMP in adipocytes, directly interacts with PGC-1α (Co-IP), induces PGC-1α and PRDM16 expression, and drives Ucp1 expression. Knockout of IRF4 in UCP1+ cells reduces thermogenic gene expression, energy expenditure, and cold tolerance; overexpression promotes all three. PGC-1α-driven thermogenic gene expression requires IRF4.\",\n      \"method\": \"Adipocyte-specific IRF4 knockout mice, IRF4 overexpression in vivo, Co-immunoprecipitation of IRF4 with PGC-1α, cold/cAMP stimulation assays, Ucp1 reporter assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout plus overexpression in vivo, protein-protein interaction by Co-IP, and multiple orthogonal functional readouts in one study\",\n      \"pmids\": [\"24995979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF4 is required in a B cell-intrinsic manner for germinal center B cell formation, independent of its role in plasma cell differentiation. Conditional deletion of Irf4 in mature B cells severely impaired GC formation as early as day 5 post-immunization. IRF4-deficient B cells in chimeric mice failed to participate in GCs after L. major or influenza infection.\",\n      \"method\": \"Conditional B cell-specific Irf4 knockout mice, mixed bone marrow chimeras, in vivo immunization models (protein antigen, L. major, influenza)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus chimeric rescue experiments with multiple immunization models, clear B cell-intrinsic phenotype\",\n      \"pmids\": [\"24591370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF4 and BATF are both necessary for sustained CD8+ T cell effector function after LCMV infection. Irf4−/− CD8+ T cells showed initial proliferation but limited effector responses, causing viral persistence and protection from fatal immunopathology in Irf4−/− mice. Absence of BATF produced a similar phenotype.\",\n      \"method\": \"Irf4−/− mouse LCMV infection model, CD8+ T cell functional assays (cytotoxicity, viral clearance), comparison to BATF-deficient mice\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockout model with defined viral infection phenotype, single lab\",\n      \"pmids\": [\"24531538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF4 concentration-dependently controls T helper cell fate: higher IRF4 levels promote Teff (Blimp-1+) fates at the expense of Tfh (Bcl6+) fates. Increased IRF4 abundance leads to its recruitment to lower-affinity binding sites in Teff cis-regulatory elements, including the Prdm1 locus. Orthogonal induction of Irf4 expression redirected Tfh cell fate toward Teff.\",\n      \"method\": \"Conditional IRF4 expression systems, ChIP-seq for IRF4 occupancy at distinct binding sites, T cell fate tracing, TCR signal strength manipulation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq, conditional expression, and fate-mapping with multiple orthogonal methods in one study\",\n      \"pmids\": [\"28930660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"mTORC2 and IL-4Rα-Stat6 pathways operate in parallel to induce IRF4 expression, which in turn drives increased glycolysis necessary for M2 (alternative) macrophage activation. Loss of mTORC2 in macrophages suppressed IRF4 induction and impaired M2 activation including glucose utilization.\",\n      \"method\": \"Myeloid-specific mTORC2 knockout mice, IL-4 stimulation assays, IRF4 expression measurements, metabolic flux assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO mouse model, pathway epistasis (mTORC2→Stat6→IRF4), and metabolic readouts with multiple methods\",\n      \"pmids\": [\"27760338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KDM3A maintains expression of KLF2 and IRF4 in multiple myeloma through H3K9 demethylation. KLF2 directly activates IRF4 transcription, and IRF4 reciprocally upregulates KLF2, forming a positive autoregulatory circuit. Knockdown of KDM3A, KLF2, or IRF4 each decreases MM cell adhesion to bone marrow stromal cells and reduces MM cell homing, associated with decreased ITGB7 expression.\",\n      \"method\": \"siRNA knockdown, ChIP for H3K9me2 at KLF2/IRF4 loci, luciferase reporter assays for KLF2→IRF4 transcriptional activation, cell adhesion and homing assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for histone marks, reporter assays, knockdown phenotypes, and functional cell biology in one study with multiple orthogonal methods\",\n      \"pmids\": [\"26728187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IRF4 and IRF8 cooperate with PU.1 to regulate early B cell development and suppress pre-B cell acute lymphoblastic leukemia. Combined PU.1/IRF4 deletion caused a partial pre-B cell developmental block and 100% leukemia incidence. PU.1/IRF4/IRF8 directly regulate Ikaros and Spi-B, established B-lineage tumor suppressor genes, and restoration of either rescued leukemic cell growth inhibition.\",\n      \"method\": \"PU.1/IRF4/IRF8 compound knockout mouse models, ChIP to show direct regulation of Ikaros and Spi-B, reconstitution of Ikaros/Spi-B in leukemic cells\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — compound KO mouse models with direct ChIP evidence of target gene regulation and rescue reconstitution experiments\",\n      \"pmids\": [\"26932576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"T cell exhaustion during chronic LCMV infection is driven by high TCR-induced IRF4, BATF, and NFATc1. These regulators promote inhibitory receptor expression (including PD-1) and impaired cellular metabolism, while repressing TCF1 required for memory T cell differentiation. Reducing IRF4 expression restored functional and metabolic properties and promoted memory-like T cell development.\",\n      \"method\": \"Transcriptional profiling of antigen-specific T cells from acute vs. chronic LCMV infection, IRF4 knockdown/reduction experiments, metabolic assays, inhibitory receptor expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transcriptional profiling plus loss-of-function with multiple phenotypic readouts (metabolism, inhibitory receptors, TCF1 expression)\",\n      \"pmids\": [\"29246443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IRF4 represses PD-1 expression and other molecules associated with T cell dysfunction in CD4+ T cells. IRF4 deletion increases chromatin accessibility at PD-1 cis-regulatory elements and enhances Helios binding there, leading to enhanced PD-1 expression and progressive CD4+ T cell dysfunction. The dysfunctional state was initially reversible by PD-1 ligand blockade.\",\n      \"method\": \"Irf4 conditional deletion in T cells, ATAC-seq for chromatin accessibility, ChIP for Helios at PD-1 cis-regulatory elements, allograft transplant model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus chromatin accessibility and ChIP at specific loci, mechanistic connection to Helios-PD1 axis established\",\n      \"pmids\": [\"29221730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ITK kinase activity is required for Tr1 cell differentiation via the Ras/IRF4 pathway. Downstream of ITK, Ras activity induces IRF4 expression; constitutively active HRas rescues IRF4 expression and Tr1 cell differentiation in Itk−/− cells. IRF4 expression in Itk-deficient cells restores Tr1 cell development and suppressive function.\",\n      \"method\": \"Itk-deficient mouse model, constitutively active HRas rescue experiments, IRF4 reconstitution in Itk−/− cells, in vitro Tr1 cell differentiation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiments placing IRF4 downstream of ITK-Ras, single lab\",\n      \"pmids\": [\"28635957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The K59R IRF4 mutant found in adult T-cell leukemia is expressed at higher levels in the nucleus than WT IRF4 and is transcriptionally more active. IRF4 is bound to genomic regulatory DNA of its transcriptional targets in HTLV-1-transformed cell lines. Overexpression of both WT and K59R IRF4 from a constitutive promoter in murine bone marrow cells increased T lymphocyte abundance in vivo.\",\n      \"method\": \"Whole-exome sequencing, ChIP of IRF4 at target loci in HTLV-1-transformed cells, nuclear/cytoplasmic fractionation comparing WT vs K59R, retroviral transduction of murine bone marrow\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, nuclear localization fractionation, and in vivo reconstitution; single lab\",\n      \"pmids\": [\"29540473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF4 activity in established plasma cells is required to regulate gene transcription specifying plasma cell identity and maintaining mitochondrial homeostasis. IRF4 loss in mature plasma cells triggers apoptosis, but this is not through direct regulation of the intrinsic apoptotic pathway; rather, inducible IRF4 deletion in the presence of BCL2 overexpression revealed the transcriptional (identity/mitochondrial) functions of IRF4 separately from its pro-survival role.\",\n      \"method\": \"Inducible Irf4 deletion system combined with BCL2 overexpression, gene expression profiling, mitochondrial function assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible KO with BCL2 rescue dissects two functions, single lab with clean genetic system\",\n      \"pmids\": [\"31775034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF4 and NF-κB co-occupy super-enhancers in ATL cells and form a coherent feed-forward loop to coordinately regulate T-cell functional/developmental genes, as well as cancer-associated genes including MYC, CCR4, and BIRC3. Genetic inhibition of BIRC3 (a downstream effector) induced growth inhibition in ATL cells.\",\n      \"method\": \"Gene expression profiling of primary ATL samples, ChIP-seq for IRF4 and NF-κB binding at super-enhancers, BIRC3 genetic knockdown, growth inhibition assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus functional knockdown, single lab\",\n      \"pmids\": [\"31972002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF4, either alone or in combination with BATF, directly controls a molecular program responsible for immunosuppression of CD4+ effector Tregs in tumors. Integration of transcriptomic and epigenomic data demonstrated direct IRF4 (and IRF4/BATF composite) binding at suppressive molecule gene loci; Irf4 deletion exclusively in Tregs delayed tumor growth in mice.\",\n      \"method\": \"Single-cell profiling, integration of transcriptomics and epigenomics (ATAC-seq/ChIP), Irf4 Treg-specific conditional knockout mouse tumor model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Treg-specific KO mouse with direct epigenomic evidence of IRF4 binding at effector loci and multiple orthogonal methods\",\n      \"pmids\": [\"32125291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structure of the IRF4/ISRE homodimeric complex revealed that homodimer formation is achieved exclusively through protein-DNA contacts with substantial DNA deformation, with no direct protein-protein contact. This contrasts with the IRF4/PU.1 heterodimeric complex where DNA-bound IRF4 physically contacts PU.1 to engage EICE1. Hotspot residues Arg98, Cys99, and Asn102 contact both consensus and non-consensus sequences via a flexible L1 loop. The CLL-associated IRF4L116R mutant binds DNA more robustly, providing a structural rationale for its gain-of-function.\",\n      \"method\": \"X-ray crystallography (crystal structure of IRF4/ISRE homodimer), mutagenesis of hotspot residues, comparison with heterodimeric complex\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis and mechanistic comparison between homo and heterodimeric forms in a single rigorous study\",\n      \"pmids\": [\"33533913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BATF and IRF4 cooperate to counter T cell exhaustion in tumor-infiltrating CAR T cells. BATF overexpression in CAR T cells promoted survival, effector cytokine production, decreased inhibitory receptor/TOX expression, and supported memory T cell generation. These responses required BATF-IRF4 interaction, as a BATF variant unable to interact with IRF4 failed to improve antitumor responses.\",\n      \"method\": \"CAR T cell mouse tumor models, BATF overexpression, BATF mutant unable to interact with IRF4 (domain interaction requirement), flow cytometry, tumor growth assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain interaction mutant as mechanistic control, in vivo tumor models, multiple phenotypic readouts\",\n      \"pmids\": [\"34282330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRF4 negatively regulates BCR signaling in CLL cells by reducing AKT and ERK phosphorylation and calcium release; it suppresses expression of SYK (a key BCR signaling kinase) and IKAROS. IKAROS in turn promotes BCR signaling by reducing SHIP1 expression. IMiDs (lenalidomide/avadomide) induce IRF4 expression while down-regulating IKAROS, interfering with BCR-triggered survival advantage.\",\n      \"method\": \"IRF4 overexpression and siRNA knockdown in CLL cells, phospho-flow cytometry for AKT/ERK, calcium flux assays, SYK and IKAROS expression measurements, SHIP1 expression analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with multiple downstream signaling readouts, single lab\",\n      \"pmids\": [\"33623139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PC4, IKAROS, and IRF4 form a complex in mature B cells (Co-IP). IRF4 reciprocally induces PC4 expression via a super-enhancer. PC4 is required for IRF4 protein to increase upon B cell activation; PC4-deficient B cells show impaired plasma cell generation.\",\n      \"method\": \"B cell-specific PC4 knockout mice, Co-IP of PC4/IKAROS/IRF4 complex, super-enhancer analysis by ChIP, plasma cell differentiation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of complex, KO mouse model, and super-enhancer ChIP, single lab\",\n      \"pmids\": [\"33357426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A heterozygous IRF4 mutation (p.T95R) in the DNA-binding domain causes autosomal dominant combined immunodeficiency by acting as a multimorphic allele: it binds DNA with higher affinity than WT (gain-of-function hypermorph), has reduced transcriptional activity on canonical IRF4 target genes (hypomorphic), and binds noncanonical DNA sites to alter gene expression (neomorphic). IRF4T95R alters B cell maturation, immunoglobulin isotype switching, plasma cell differentiation, and TH17/TFH T cell populations.\",\n      \"method\": \"Patient genetics, knock-in mouse model of T95R, DNA binding affinity assays, transcriptomic profiling of patient cells, motif analysis of canonical vs. noncanonical binding sites\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — knock-in mouse model, direct DNA-binding affinity measurement, transcriptomic characterization, and mechanistic classification of multimorphic allele\",\n      \"pmids\": [\"36662884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A heterozygous IRF4 missense variant in the interferon activation domain causes dominant primary immunodeficiency by altering IRF4 protein-protein interactions (identified by rapid immunoprecipitation mass spectrometry of endogenous proteins). Mutant IRF4 fails to efficiently regulate ISRE transcriptional activity and reduces BLIMP-1 and XBP1 expression, blocking plasma cell differentiation.\",\n      \"method\": \"Patient genetics, immunoprecipitation mass spectrometry of endogenous IRF4 protein partners, ISRE reporter assays, BLIMP-1/XBP1 expression in patient B cell lines\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous Co-IP mass spectrometry plus functional reporter assays and patient B cell lines, single study\",\n      \"pmids\": [\"36917008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IRF4 in skeletal muscle transcriptionally regulates FSTL1 expression (established by dual luciferase reporter assay). Muscle-secreted FSTL1 acts on liver cells via distinct receptors (DIP2A/CD14) to regulate hepatic steatosis, inflammation, and fibrosis, defining an IRF4-FSTL1-DIP2A/CD14 inter-organ endocrine axis in NASH.\",\n      \"method\": \"Skeletal muscle-specific IRF4 knockout mice, proteomics, dual luciferase reporter assay for IRF4→FSTL1 transcription, co-culture experiments, AAV-mediated FSTL1 rescue in F4MKO mice\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO, luciferase reporter for direct transcriptional regulation, in vivo rescue by AAV-FSTL1, and co-culture mechanistic validation in one study\",\n      \"pmids\": [\"37770480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IRF4 functions as a signal integrator in NK cells during cytomegalovirus infection, coordinating nutrient uptake (glucose and amino acid transport) necessary for NK cell expansion, differentiation, and memory generation. IRF4-deficient virus-specific NK cells were impaired in nutrient uptake and failed to expand or form memory.\",\n      \"method\": \"Irf4 conditional knockout in NK cells, MCMV infection model, nutrient uptake assays (glucose/amino acid transport), clonal expansion and memory NK cell assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO in NK cells with direct metabolic/nutrient uptake readouts, single lab\",\n      \"pmids\": [\"37697097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The somatic mutation IRF4-C99R in Hodgkin lymphoma causes a fundamental alteration of IRF4 DNA binding: loss of binding to canonical IRF motifs and neomorphic gain of binding to canonical and non-canonical IRF composite elements (AICEs). IRF4-C99R blocks IRF4-dependent plasma cell induction and upregulates disease-specific genes in a non-canonical AICE-dependent manner.\",\n      \"method\": \"ChIP-seq of IRF4-C99R vs. WT in lymphoma cells, gene expression profiling, plasma cell differentiation assays, AICE motif analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq demonstrating altered DNA binding specificity, functional differentiation assays, motif-level mechanistic explanation\",\n      \"pmids\": [\"37935654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID1A, a SWI/SNF complex member, is required for IRF4 expression in multiple myeloma and physically associates with IRF4 on chromatin. Deleting Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and blocks plasma cell differentiation. SWI/SNF inhibition causes rapid loss of IRF4-target gene expression and quenches MYC-driven oncogenic gene amplification.\",\n      \"method\": \"Multi-omics (functional genomics screening, spatial proteomics, chromatin mapping), co-occupancy of ARID1A and IRF4 by ChIP, Arid1a conditional KO in B cells, SMARCA2/4 inhibitor experiments\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO, chromatin co-occupancy, multi-omics, and pharmacological validation with multiple orthogonal methods\",\n      \"pmids\": [\"38906156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PU.1 and IRF4 form a heterodimer that synergistically transactivates the Aldh1a2 (RALDH2) gene via an EICE motif at −1961/−1952 in dendritic cells. ChIP assays confirmed that both PU.1 and IRF4 bind the Aldh1a2 gene ~2 kb upstream of the TSS in bone marrow-derived and ex vivo DCs. Knockdown of either factor reduced RALDH2 mRNA and enzymatic activity.\",\n      \"method\": \"ChIP assay, EMSA, luciferase reporter assay, siRNA knockdown in BMDCs, ex vivo DC analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, EMSA, reporter and knockdown experiments in both in vitro and ex vivo systems, single lab\",\n      \"pmids\": [\"30413670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRAK4 phosphorylates both IRF4 and IRF5 in microglia, and forms a Myddosome complex with MyD88/IRF5/IRF4. Phosphorylated IRF4 translocates to the nucleus to drive anti-inflammatory microglial responses. IRAK4 inhibition blocks IRF4/IRF5 phosphorylation, reduces pro-inflammatory response, and increases neuronal viability after ischemia.\",\n      \"method\": \"Co-immunoprecipitation/Western blot of Myddosome complex, IRAK4 inhibitor treatment, nuclear translocation assays, OGD model in microglial cells\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of complex, pharmacological inhibition with multiple readouts, single lab\",\n      \"pmids\": [\"33573200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF4 in skeletal muscle regulates glycogen metabolism by transcriptionally controlling PTG (protein targeting to glycogen). IRF4 knockout in skeletal muscle increases glycogen content and exercise capacity; IRF4 overexpression decreases both. PTG knockdown reverses the effects of IRF4 absence in vivo.\",\n      \"method\": \"Skeletal muscle-specific IRF4 knockout and overexpression mice, PTG knockdown in vivo, glycogen content measurements, exercise capacity assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO and OE plus in vivo rescue knockdown of downstream target PTG, single lab\",\n      \"pmids\": [\"33042761\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IRF4 is a lymphoid- and immune-cell-restricted transcription factor that binds DNA as a homodimer (exclusively through protein-DNA contacts with DNA deformation) or as a heterodimer with partners such as PU.1 (via protein-protein contact on DNA at EICE/AICE elements), with binding-site affinity and partner availability determining whether it activates or represses target genes; it acts as a concentration-dependent signal integrator downstream of antigen receptor and cytokine signals to control B cell germinal center entry, class-switch recombination, and plasma cell differentiation (upstream of Blimp-1 and XBP-1), CD4+ T helper fate choice (Tfh vs. Teff), CD8+ T cell effector function and exhaustion, NK cell memory, macrophage alternative activation (via mTORC2-Stat6-IRF4-glycolysis axis), adipocyte thermogenesis (through direct interaction with PGC-1α), and skeletal muscle glycogen/FSTL1-mediated inter-organ crosstalk, while in malignancy it forms autoregulatory circuits with MYC and NF-κB and is maintained by epigenetic regulators including KDM3A and ARID1A/SWI/SNF.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IRF4 is a lymphoid- and immune-cell-restricted transcription factor that integrates antigen-receptor and cytokine signals to direct cell-fate decisions across the immune system and several metabolic tissues [#0, #13]. Originally identified as a lymphoid-specific IRF-family member that binds ISRE elements yet is induced by antigen-receptor stimuli rather than interferons, it acts as both repressor and activator depending on the DNA motif engaged and its partner proteins [#0, #1]. Structurally, IRF4 binds canonical ISRE sites as a homodimer formed exclusively through protein-DNA contacts with substantial DNA deformation and no protein-protein interface, whereas it engages composite EICE/AICE elements as a heterodimer in which DNA-bound IRF4 physically contacts partners such as PU.1 and BATF [#24, #2, #25]. This concentration-dependent occupancy of high- versus low-affinity sites underlies its role as a signal integrator: in B cells IRF4 is required cell-intrinsically for germinal center formation, class-switch recombination, and post-germinal-center plasma cell differentiation upstream of Blimp-1 and XBP-1, and maintains plasma cell identity and mitochondrial homeostasis [#11, #4, #21]. In T cells, graded IRF4 abundance steers Teff versus Tfh fate by redirecting occupancy to lower-affinity sites at the Prdm1 locus, sustains CD8+ effector function with BATF, and at high TCR-driven levels promotes exhaustion while repressing PD-1 in CD4+ cells [#13, #12, #17, #18]. Beyond lymphocytes, IRF4 drives M2 macrophage activation via an mTORC2-Stat6-IRF4-glycolysis axis, coordinates nutrient uptake for NK cell memory, partners with PGC-1\\u03b1 to control adipocyte thermogenesis, and transcriptionally governs muscle glycogen (via PTG) and FSTL1-mediated inter-organ crosstalk [#14, #31, #10, #36, #30]. In malignancy IRF4 forms autoregulatory circuits with MYC and NF-\\u03baB and is maintained by epigenetic regulators KDM3A and ARID1A/SWI/SNF, acting as an essential survival factor in myeloma yet a tumor suppressor in c-Myc-driven and chronic lymphocytic leukemias [#5, #22, #15, #33, #7, #9]. Heterozygous DNA-binding-domain mutations (p.T95R, multimorphic) and interferon-activation-domain variants cause autosomal dominant combined immunodeficiency by altering DNA-binding specificity and protein interactions [#28, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing IRF4 as a lymphoid-restricted IRF-family factor induced by antigen-receptor rather than interferon signals separated it from the classical interferon-response IRFs and pointed to a role in adaptive immunity.\",\n      \"evidence\": \"PCR cloning and in vitro ISRE-binding assays in lymphoid cells\",\n      \"pmids\": [\"7541907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro binding only; physiological target genes not defined\", \"No loss-of-function phenotype established\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that IRF4 can repress interferon-induced gene activation, with motif-dependent binding affinities, framed it as a context-dependent regulator rather than a simple activator.\",\n      \"evidence\": \"Cotransfection reporter assays and in vitro DNA-binding affinity comparisons\",\n      \"pmids\": [\"8657101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Activator versus repressor switch not yet mechanistically explained\", \"No partner protein identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Reconstitution of a cooperative PU.1-IRF4 ternary complex on immunoglobulin enhancers defined the partner-dependent heterodimeric binding mode and mapped the IRF4 DNA-binding domain.\",\n      \"evidence\": \"Fluorescence polarization binding, NMR, and truncation mapping of PU.1/IRF4 domains\",\n      \"pmids\": [\"9642085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length protein behavior not tested\", \"Genomic target repertoire of the complex unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Conditional deletion in germinal center B cells placed IRF4 upstream of Blimp-1 and XBP-1, defining it as a master regulator of class-switch recombination and plasma cell differentiation.\",\n      \"evidence\": \"Cre-lox conditional knockout mice with CSR, AID, and epistasis readouts\",\n      \"pmids\": [\"16767092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IRF4 target genes in this cascade not fully enumerated\", \"Mechanism of concentration-dependent fate control not yet addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genome-wide ChIP plus an RNAi lethality screen revealed an IRF4-MYC autoregulatory circuit essential for myeloma survival, establishing IRF4 as an oncogenic dependency.\",\n      \"evidence\": \"Genome-wide ChIP, expression profiling, and RNAi loss-of-function screen in myeloma lines\",\n      \"pmids\": [\"18568025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream maintenance of IRF4 in myeloma not defined here\", \"Does not reconcile oncogenic versus tumor-suppressor contexts\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mouse genetics in distinct leukemia models showed IRF4 acts as a tumor suppressor in c-Myc-driven B-cell leukemia and cooperates redundantly with IRF8 in myeloid lineages, revealing strong context-dependence of its oncogenic role.\",\n      \"evidence\": \"E\\u03bcMyc/IRF4+/- mice with reconstitution, and Irf8/Irf4 double-knockout myeloid models\",\n      \"pmids\": [\"21818355\", \"22003407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis distinguishing tumor-suppressor versus oncogene roles unresolved\", \"p27/Arf-p53 link correlative for direct regulation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Reciprocal genetics identified Smad2/3 as a physical IRF4 partner cooperatively activating Il9, and IRF4-deficient mouse models linked low IRF4 causally to CLL, extending its partner repertoire and tumor-suppressor function.\",\n      \"evidence\": \"Co-IP, ChIP at Il9, knockout T cells, and IRF4-/-Vh11 CLL mouse model with reconstitution\",\n      \"pmids\": [\"23913959\", \"23926303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Smad2/3-IRF4 interface not structurally mapped\", \"CLL tumor-suppressor mechanism downstream of IRF4 incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A cluster of studies established IRF4 as a B-cell-intrinsic requirement for germinal center entry, a BATF-dependent driver of CD8 effector function, and—surprisingly—a thermogenic transcription factor partnering PGC-1\\u03b1 in adipocytes, broadening its biology beyond lymphocytes.\",\n      \"evidence\": \"Conditional/chimeric B-cell and CD8 knockout infection models, plus adipocyte-specific KO/overexpression with PGC-1\\u03b1 Co-IP\",\n      \"pmids\": [\"24591370\", \"24531538\", \"24995979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IRF4 targets in each lineage incompletely mapped\", \"How one factor switches between immune and metabolic programs unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mechanistic dissection showed IRF4 abundance is set by parallel mTORC2-Stat6 input to drive M2 macrophage glycolysis, and that PU.1/IRF4/IRF8 jointly suppress B-ALL via Ikaros/Spi-B, while KDM3A-KLF2 maintains IRF4 in myeloma—connecting upstream signaling, epigenetics, and lineage tumor suppression.\",\n      \"evidence\": \"Myeloid mTORC2 KO with metabolic flux, compound PU.1/IRF4/IRF8 KO mice with ChIP/rescue, and KDM3A H3K9me ChIP/reporter/adhesion assays\",\n      \"pmids\": [\"27760338\", \"26932576\", \"26728187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mechanism coupling IRF4 to glycolytic gene induction not fully resolved\", \"How IRF4 partitions oncogenic versus suppressive output across lineages unexplained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Quantitative studies defined IRF4 as a concentration-dependent signal integrator: graded levels redirect occupancy from high- to low-affinity Teff cis-elements (Tfh/Teff choice), while sustained high TCR-driven IRF4 promotes exhaustion yet IRF4 also represses PD-1 via chromatin control, resolving its dual role in T-cell function.\",\n      \"evidence\": \"ChIP-seq/conditional expression for Tfh/Teff, chronic LCMV profiling with IRF4 reduction, ATAC-seq/Helios ChIP at PD-1 elements, and ITK-Ras-IRF4 rescue\",\n      \"pmids\": [\"28930660\", \"29246443\", \"29221730\", \"28635957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold-setting kinetics of IRF4 protein in vivo not quantified\", \"Apparently opposing PD-1 effects across contexts not fully reconciled\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Cancer-mutation and DC studies showed IRF4 activity is tuned by nuclear abundance (K59R in ATL) and by EICE-dependent synergy with PU.1 at the Aldh1a2 locus, linking gain-of-function mutations and partner cooperativity to altered output.\",\n      \"evidence\": \"Exome sequencing, ChIP and nuclear fractionation of WT vs K59R, plus ChIP/EMSA/reporter/knockdown of PU.1-IRF4 at Aldh1a2 in DCs\",\n      \"pmids\": [\"29540473\", \"30413670\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism elevating K59R nuclear levels undefined\", \"Single-lab observations awaiting independent confirmation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Separating IRF4's survival from identity functions using inducible deletion plus BCL2 rescue showed IRF4 maintains plasma cell identity and mitochondrial homeostasis through transcription independent of direct apoptotic control.\",\n      \"evidence\": \"Inducible Irf4 deletion with BCL2 overexpression, expression profiling, mitochondrial assays\",\n      \"pmids\": [\"31775034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mitochondrial target genes not defined\", \"Single genetic system\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genome-wide and tissue-specific work established IRF4-NF-\\u03baB feed-forward super-enhancer circuits in ATL, IRF4-directed Treg immunosuppression, and IRF4 control of muscle glycogen via PTG, unifying its roles in malignancy, tumor immunity, and metabolism.\",\n      \"evidence\": \"ChIP-seq of IRF4/NF-\\u03baB at super-enhancers with BIRC3 knockdown, Treg-specific Irf4 KO tumor model with epigenomics, and muscle IRF4 KO/OE with PTG rescue\",\n      \"pmids\": [\"31972002\", \"32125291\", \"33042761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How super-enhancer co-occupancy is nucleated unclear\", \"Direct versus indirect metabolic targets only partly resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A crystal structure resolved the contact-free homodimeric versus PU.1-contacting heterodimeric binding modes and rationalized CLL gain-of-function (L116R), while functional studies extended IRF4 partnerships to BATF (anti-exhaustion in CAR T), the PC4/IKAROS complex, and BCR-signaling suppression in CLL.\",\n      \"evidence\": \"X-ray crystallography with hotspot mutagenesis, CAR T tumor models with BATF interaction-deficient mutant, PC4/IKAROS/IRF4 Co-IP, and CLL gain/loss-of-function signaling assays\",\n      \"pmids\": [\"33533913\", \"34282330\", \"33357426\", \"33623139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of heterodimers beyond PU.1 not solved\", \"In vivo relevance of PC4/IKAROS complex incompletely defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Human germline IRF4 mutations (multimorphic p.T95R, interferon-activation-domain variant) were shown to cause autosomal dominant immunodeficiency, and somatic C99R in Hodgkin lymphoma was shown to neomorphically rewire DNA-binding to AICEs, formally linking altered DNA-binding/partner specificity to disease; parallel work extended IRF4 to NK-cell memory metabolism and a muscle-FSTL1-liver endocrine axis.\",\n      \"evidence\": \"Knock-in mice and patient cells with binding/transcriptomic profiling, ChIP-seq of C99R, NK-specific KO with nutrient-uptake assays, and muscle-specific KO with FSTL1 reporter/AAV rescue\",\n      \"pmids\": [\"36662884\", \"36917008\", \"37935654\", \"37697097\", \"37770480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype spectrum of multimorphic alleles incompletely mapped\", \"Receptors/effectors downstream in metabolic axes only partly defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying ARID1A/SWI/SNF as a chromatin partner required for IRF4 expression and IRF4-target/MYC oncogenic programs in myeloma defined a therapeutically actionable epigenetic dependency maintaining IRF4 networks.\",\n      \"evidence\": \"Multi-omics with ARID1A-IRF4 chromatin co-occupancy, Arid1a B-cell KO, and SMARCA2/4 inhibitor experiments\",\n      \"pmids\": [\"38906156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interface between ARID1A and IRF4 not mapped\", \"Generalizability beyond myeloma untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single transcription factor mechanistically partitions opposing outputs—oncogene versus tumor suppressor, effector versus exhaustion, immune versus metabolic programs—across cell types remains the central open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking IRF4 dose, partner availability, and site affinity to lineage-specific output\", \"Post-translational control of IRF4 abundance/localization across tissues incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 4, 13, 24, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 24, 28, 32]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 8, 10, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20, 35]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [13, 32, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 11, 13, 14, 31]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 24, 32]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 22, 28, 32, 33]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [10, 14, 30, 36]}\n    ],\n    \"complexes\": [\n      \"IRF4/PU.1 heterodimer\",\n      \"IRF4/BATF complex\",\n      \"PC4/IKAROS/IRF4 complex\",\n      \"MyD88/IRF5/IRF4 Myddosome\"\n    ],\n    \"partners\": [\n      \"SPI1\",\n      \"BATF\",\n      \"SMAD3\",\n      \"PPARGC1A\",\n      \"IKZF1\",\n      \"SUB1\",\n      \"ARID1A\",\n      \"IRF8\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}